Akiyama Hironori, Yoshida Ken, Yamazaki Hideya, Takenaka Tadashi, Kotsuma Tadayuki, Masui Koji, Yoshioka Yasuo, Arika Takumi, Shimizutani Kimishige, Tanaka Eiichi
Department of Oral Radiology, Osaka Dental University, Japan.
Department of Radiology, Osaka Medical College, Japan.
J Contemp Brachytherapy. 2014 Mar;6(1):10-4. doi: 10.5114/jcb.2014.40726. Epub 2014 Feb 19.
To compare the outcome of our facility with another about the shortened schedule (60 Gy in 10 fractions to 54 Gy in 9 fractions) of high-dose-rate interstitial brachytherapy (HDR ISBT) for mobile tongue cancer.
Eighteen patients were treated with HDR ISBT as a monotherapy in dose reduction schedule with some unique technique to determine the border of tumor accuracy (lugol's staining and metal marker), and to minimize adverse effect (lead-lined silicon block) at our facility.
The 2-year local and regional control rates and cause-specific survival rate were 82%, 80%, and 83% and moderate to severe late complications occurred in five patients (28%), which were almost the same treatment results achieved by another facility.
We recommend 54 Gy in 9 fractions over 7 days as a feasible treatment to reduce patient discomfort in mobile tongue cancer patients.
比较我院与另一机构关于高剂量率组织间近距离放疗（HDR ISBT）缩短疗程（从10次分割给予60 Gy减至9次分割给予54 Gy）治疗活动期舌癌的疗效。
18例患者在我院接受HDR ISBT单药治疗，采用剂量缩减方案，并运用一些独特技术来确定肿瘤边界的准确性（卢戈氏染色和金属标记），以及将不良反应降至最低（铅衬硅块）。
2年局部和区域控制率以及特定病因生存率分别为82%、80%和83%，5例患者（28%）出现中度至重度晚期并发症，这与另一机构所取得的治疗结果几乎相同。
我们推荐7天内9次分割给予54 Gy作为一种可行的治疗方案，以减轻活动期舌癌患者的不适。
